cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.22496009
title: A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark

description: The recommended first-line treatment for advanced, ER+/HER2 negative breast cancer is a CDK 4/6 inhibitor in combination with an endocrine backbone. This study investigated the use of palbociclib, as first- or second-line therapy for advanced breast cancer patients in a real-world setting. This retrospective, population-based study included all Danish, advanced breast cancer patients with ER+/HER2 negative disease who initiated first- or second-line treatment with palbociclib from January 1<sup>st</sup>, 2017, until December 31<sup>st</sup>, 2020. The primary outcomes were PFS and OS. The study included 1054 advanced breast cancer patients with a mean age of 66.8 years. Median OS was 51.7 months (95% CI, 44.9–54.6) for all patients in the first-line setting (<i>n</i> = 728) and median PFS was 24.3 months (95% CI, 21.7–27.8). Patients treated in second line (<i>n</i> = 326) had a median OS of 32.5 months (95% CI, 29.9–35.9) and a median PFS of 13.6 months (95% CI, 11.5–15.7). In first-line setting, the PFS and OS were significantly different for endocrine sensitive patients treated with AI (aromatase inhibitor) (<i>n</i> = 423) vs. fulvestrant (<i>n</i> = 158) as endocrine backbone to palbociclib (median PFS AI 31.3 months vs fulvestrant 19.9 months, <i>p</i> = 0.002 and median OS AI 56.9 months vs. fulvestrant 43.6 months, <i>p</i> = 0.001). In endocrine resistant patients (<i>n</i> = 145), no statistically significant difference in PFS was shown (median PFS AI 21.5 months vs. fulvestrant 12.0 months, <i>p</i> = 0.09), whereas OS was significantly different (median OS AI 43.5 months vs. fulvestrant 28.8 months, <i>p</i> = 0.02). In this real-world study, treatment with palbociclib combination therapy met the standards of efficacy set by the phase III trials, PALOMA-2 and PALOMA-3, and the standards set by real-world studies in other countries. The study showed significantly different outcomes in terms of PFS and OS in endocrine sensitive patients comparing AI vs. fulvestrant as endocrine backbone to palbociclib as first-line therapy.
DOI: 10.6084/m9.figshare.22496009.v1
title: A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark

description: The recommended first-line treatment for advanced, ER+/HER2 negative breast cancer is a CDK 4/6 inhibitor in combination with an endocrine backbone. This study investigated the use of palbociclib, as first- or second-line therapy for advanced breast cancer patients in a real-world setting. This retrospective, population-based study included all Danish, advanced breast cancer patients with ER+/HER2 negative disease who initiated first- or second-line treatment with palbociclib from January 1<sup>st</sup>, 2017, until December 31<sup>st</sup>, 2020. The primary outcomes were PFS and OS. The study included 1054 advanced breast cancer patients with a mean age of 66.8 years. Median OS was 51.7 months (95% CI, 44.9–54.6) for all patients in the first-line setting (<i>n</i> = 728) and median PFS was 24.3 months (95% CI, 21.7–27.8). Patients treated in second line (<i>n</i> = 326) had a median OS of 32.5 months (95% CI, 29.9–35.9) and a median PFS of 13.6 months (95% CI, 11.5–15.7). In first-line setting, the PFS and OS were significantly different for endocrine sensitive patients treated with AI (aromatase inhibitor) (<i>n</i> = 423) vs. fulvestrant (<i>n</i> = 158) as endocrine backbone to palbociclib (median PFS AI 31.3 months vs fulvestrant 19.9 months, <i>p</i> = 0.002 and median OS AI 56.9 months vs. fulvestrant 43.6 months, <i>p</i> = 0.001). In endocrine resistant patients (<i>n</i> = 145), no statistically significant difference in PFS was shown (median PFS AI 21.5 months vs. fulvestrant 12.0 months, <i>p</i> = 0.09), whereas OS was significantly different (median OS AI 43.5 months vs. fulvestrant 28.8 months, <i>p</i> = 0.02). In this real-world study, treatment with palbociclib combination therapy met the standards of efficacy set by the phase III trials, PALOMA-2 and PALOMA-3, and the standards set by real-world studies in other countries. The study showed significantly different outcomes in terms of PFS and OS in endocrine sensitive patients comparing AI vs. fulvestrant as endocrine backbone to palbociclib as first-line therapy.
DOI: 10.6084/m9.figshare.22140539
title: Sarcopenia and loss of muscle mass in patients with lung cancer undergoing chemotherapy treatment: a systematic review and meta-analysis

description: In patients with cancer, sarcopenia is associated with treatment related complications, treatment cessation, poor quality of life and reduced overall survival. Despite this, there is limited knowledge about changes in skeletal muscle mass during chemotherapy. The aim of this systematic review and meta-analysis was to investigate the change of skeletal muscle mass and sarcopenia during chemotherapy treatment among patients with lung cancer. A systematic literature search was conducted in three databases, PubMed, EMBASE and Web of Science. Observational studies with patients with lung cancer were eligible for inclusion if skeletal muscle mass was measured before and after receiving chemotherapy treatment. Ten cohort studies with a total of 867 participants met the inclusion criteria. During 5.2 ± 2.9 months of chemotherapy treatment, patients with lung cancer experienced a significant loss of skeletal muscle mass with a standardized mean difference (SMD) of: -0.25 (95% CI -0.47 to -0.03). The pretreatment prevalence of sarcopenia varied across studies from 35% to 74%. Only one study reported prevalence of sarcopenia both before and after chemotherapy treatment with an increase from 35% to 59%. The present data demonstrate a marked loss of skeletal muscle mass in patients with lung cancer undergoing chemotherapy treatment, as well as a high prevalence of sarcopenia. As sarcopenia is associated with poor clinical outcomes, it seems important to include and use assessments of skeletal muscle mass in clinical practice to identify patients in need for interventions. Moreover, interventional studies to hinder development of sarcopenia are needed.
DOI: 10.6084/m9.figshare.22140539.v2
title: Sarcopenia and loss of muscle mass in patients with lung cancer undergoing chemotherapy treatment: a systematic review and meta-analysis

description: In patients with cancer, sarcopenia is associated with treatment related complications, treatment cessation, poor quality of life and reduced overall survival. Despite this, there is limited knowledge about changes in skeletal muscle mass during chemotherapy. The aim of this systematic review and meta-analysis was to investigate the change of skeletal muscle mass and sarcopenia during chemotherapy treatment among patients with lung cancer. A systematic literature search was conducted in three databases, PubMed, EMBASE and Web of Science. Observational studies with patients with lung cancer were eligible for inclusion if skeletal muscle mass was measured before and after receiving chemotherapy treatment. Ten cohort studies with a total of 867 participants met the inclusion criteria. During 5.2 ± 2.9 months of chemotherapy treatment, patients with lung cancer experienced a significant loss of skeletal muscle mass with a standardized mean difference (SMD) of: -0.25 (95% CI -0.47 to -0.03). The pretreatment prevalence of sarcopenia varied across studies from 35% to 74%. Only one study reported prevalence of sarcopenia both before and after chemotherapy treatment with an increase from 35% to 59%. The present data demonstrate a marked loss of skeletal muscle mass in patients with lung cancer undergoing chemotherapy treatment, as well as a high prevalence of sarcopenia. As sarcopenia is associated with poor clinical outcomes, it seems important to include and use assessments of skeletal muscle mass in clinical practice to identify patients in need for interventions. Moreover, interventional studies to hinder development of sarcopenia are needed.
DOI: 10.22008/promice/data/watson_river_discharge
title: Programme for monitoring of the Greenland ice sheet (PROMICE): Watson river discharge
DOI: 10.6084/m9.figshare.24751929
title: Transboundary_neighboring_map_data

description: There are 3 layer files in Geodatabase, including origin data for identifying the introduction, establishment, and overall invasion risk at a spatial resolution of 0.5°and 1° grids, and the richness and risk level of various groups of establishment alien vertebrates among grids and pairwise borders. The Excel data describing details of layer files, named "Data_information" is also included in the compressed file.
DOI: 10.6084/m9.figshare.24751929.v1
title: Transboundary_neighboring_map_data

description: There are 3 layer files in Geodatabase, including origin data for identifying the introduction, establishment, and overall invasion risk at a spatial resolution of 0.5°and 1° grids, and the richness and risk level of various groups of establishment alien vertebrates among grids and pairwise borders. The Excel data describing details of layer files, named "Data_information" is also included in the compressed file.
DOI: 10.34777/3p0j-6w24
title: SLURP-Fr Real

description: This is the real test portion of the SLURP-Fr dataset, which is a part of the dataset created for the studies on interpreter-aided spoken language understanding (SLU).
DOI: 10.34777/gavv-tv50
title: SLURP-Fr/Es

description: This is the synthetic portion of the SLURP-Fr and SLURP-Es dataset, which are parts of the dataset created for the studies on interpreter-aided spoken language understanding (SLU).
DOI: 10.25345/c5qn5zp01
title: MassIVE MSV000093595 - Detection of 187AA by mass spectrometry
title: Identification of 187AA unique peptides by mass spectrometry and detection of 187AA by mass spectrometry in human cells (GZF2-iPSC, GZF2-hep, 293T, SK-hep1, ESC-derived cardiomyocytes, Hep-G2 and Hela).
DOI: 10.5517/ccdc.csd.cc2dx4zg
title: CCDC 2231596: Experimental Crystal Structure Determination

description: Related Article: Johnathan Rabb|2022|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5281/zenodo.8177512
title: MIG-seq data of Rhopalomastix javana complex

description: MIG-seq data of Rhopalomastix javana complex, used in Wang & Yamada (2023).
Rhopalomastix_javana_MIG-seq_raw_reads.zip: raw demultiplexed reads (fastq) data obtained for 50 Rhopalomastix samples (including poor quolity samples which was ommited from analysis in the study).
processed_MIG-seq_data_used_for_assembry.zip: processed (fastq) data of 38 samples used for de novo assembry by ipyrad and downstream analysis (after filtering out adapter sequences and pooling R1 and R2 reads for each sample).
Wang WY & Yamada A. 2023.Scrutinising an inscrutable bark-nesting ant: Exploring cryptic diversity in the Rhopalomastix javana (Hymenoptera: Formicidae) complex using DNA barcodes, genome-wide MIG-seq and geometric morphometrics. PeerJ 11:e16416.
DOI: 10.5281/zenodo.8177513
title: MIG-seq data of Rhopalomastix javana complex

description: MIG-seq data of Rhopalomastix javana complex, used in Wang & Yamada (2023).
Rhopalomastix_javana_MIG-seq_raw_reads.zip: raw demultiplexed reads (fastq) data obtained for 50 Rhopalomastix samples (including poor quolity samples which was ommited from analysis in the study).
processed_MIG-seq_data_used_for_assembry.zip: processed (fastq) data of 38 samples used for de novo assembry by ipyrad and downstream analysis (after filtering out adapter sequences and pooling R1 and R2 reads for each sample).
Wang WY & Yamada A. 2023.Scrutinising an inscrutable bark-nesting ant: Exploring cryptic diversity in the Rhopalomastix javana (Hymenoptera: Formicidae) complex using DNA barcodes, genome-wide MIG-seq and geometric morphometrics. PeerJ 11:e16416.
DOI: 10.5281/zenodo.3736417
title: MIG-seq and molphometric datasets of the Gnamptogenys taivanensis group

description: This is old version include some errors. Please see the newer version. MIG-seq and molphometric dasatsets of the Gnamptogenys taivanensis group used in Nguyen et al. (2020) DOI: 10.26107/RBZ-2020-0070
DOI: 10.5281/zenodo.3736416
title: MIG-seq and molphometric datasets of the Gnamptogenys taivanensis group

description: MIG-seq and molphometric dasatsets of the Gnamptogenys taivanensis group used in Nguyen et al. (2020).Some errors in two csv files were corrected in this version at 2020-11-26.
DOI: 10.5281/zenodo.4291125
title: MIG-seq and molphometric datasets of the Gnamptogenys taivanensis group

description: MIG-seq and molphometric dasatsets of the Gnamptogenys taivanensis group used in Nguyen et al. (2020).Some errors in two csv files were corrected in this version at 2020-11-26.
DOI: 10.22008/promice/data/sentinel3_greenland_albedo
title: SICE v1.4 data after Kokhanovsky et al (2018, 2019, 2020)
DOI: 10.5290/6530001
title: Uniaxial tensile test data for AISI 316L sa material at 320 °C (specimen identifier AMSA 02_SideA_OPS)

description: Test data produced at the University of Manchester (United Kingdom) during the POEAM round-robin initiative on constant extension rate tensile (CERT) testing of additively manufactured (laser powder bed fusion, LPBF) 316L stainless steel under simulated LWR conditions.
DOI: 10.5290/6530002
title: Uniaxial tensile test data for AISI 316L sa material at 320 °C (specimen identifier AMSA 02_SideB_P1200)

description: Test data produced at the University of Manchester (United Kingdom) during the POEAM round-robin initiative on constant extension rate tensile (CERT) testing of additively manufactured (laser powder bed fusion, LPBF) 316L stainless steel under simulated LWR conditions.
DOI: 10.5290/6530003
title: Uniaxial tensile test data for AISI 316L sr material at 320 °C (specimen identifier AMSR 02_Side A_OPS)

description: Test data produced at the University of Manchester (United Kingdom) during the POEAM round-robin initiative on constant extension rate tensile (CERT) testing of additively manufactured (laser powder bed fusion, LPBF) 316L stainless steel under simulated LWR conditions.
DOI: 10.5290/6530004
title: Uniaxial tensile test data for AISI 316L sr material at 320 °C (specimen identifier AMSR 02_Side B_P1200)

description: Test data produced at the University of Manchester (United Kingdom) during the POEAM round-robin initiative on constant extension rate tensile (CERT) testing of additively manufactured (laser powder bed fusion, LPBF) 316L stainless steel under simulated LWR conditions.
DOI: 10.5290/6560001
title: Uniaxial tensile test data for AISI 316L sa material at 300 °C (specimen identifier SA10)

description: Test data produced at Mines Paris - Université PSL, France during the POEAM round-robin initiative on constant extension rate tensile (CERT) testing of additively manufactured (laser powder bed fusion, LPBF) 316L stainless steel under simulated LWR conditions.
DOI: 10.5290/6560002
title: Uniaxial tensile test data for AISI 316L sr material at 300 °C (specimen identifier SR6)

description: Test data produced at Mines Paris - Université PSL, France during the POEAM round-robin initiative on constant extension rate tensile (CERT) testing of additively manufactured (laser powder bed fusion, LPBF) 316L stainless steel under simulated LWR conditions.
DOI: 10.5281/zenodo.7957172
title: Vertical distribution and seasonal dynamics of planktonic cyanobacteria communities in a water column of deep mesotrophic Lake Geneva
DOI: 10.5281/zenodo.7957171
title: Vertical distribution and seasonal dynamics of planktonic cyanobacteria communities in a water column of deep mesotrophic Lake Geneva
DOI: 10.20394/1ypb3org
title: Glasgow Valuation Roll Data

description: UBDC has received from Glasgow City Assessor Valuation Roll data for the period 1995 to 2018. The data contains an entry for all non domestic properties in the Glasgow City Assessor areas, except those specifically excluded by law. Each entry in the Roll includes the Net Annual Value which has been set by the Assessor and the Rateable Value, as well as location and property description. 

##Access and Restrictions##
Safeguarded data available for academic research only in the UK under UBDC’s End User Licence Agreement. 

##Access to the Data##
In order to access Glasgow Valuation Roll Data, please get in touch with UBDC using the 
[UBDC Data Application Form](https://ubdc.ac.uk/data-services/data-services/access-our-services/ "Title")
DOI: 10.5281/zenodo.10280663
title: Russian Short-Term Mortality Fluctuations database

description: 1. Database contents
The Russian Short-Term Mortality Fluctuations database (RusSTMF) contains a series of standardized and crude death rates for men, women and both sexes for Russia as a whole and its regions for the period from 2000 to 2021.
All the output indicators presented in the database are calculated based on data of deaths registered by the Vital Registry Office. The weekly death counts are calculated based on depersonalized individual data provided by the Russian Federal State Statistics Service (Rosstat) at the request of the HSE. Time coverage: 03.01.2000 (Week 1) – 31.12.2021 (Week 1148)
2. A brief description of the input data on deaths
Date of death: date of occurrence
Unit of time: week
First and last days of the week: Monday – Sunday
First and last week of the year: The weeks are organized according to ISO 8601:2004 guidelines. Each week of the year, including the first and last, contains 7 days. In order to get 7-day weeks, the days of previous years are included in this first week (if January 1 fell on Tuesday, Wednesday or Thursday) or in the last calendar week (if December 31 fell on Thursday, Friday or Saturday).
Age groups: the entire population
Sex: men, women, both sexes (men and women combined)
Restrictions and data changes: data on deaths in the Pskov region were excluded for weeks 9-13 of 2012
Note: Deaths with an unknown date of occurrence (unknown year, month, or day) account for about 0.3% of all deaths and are excluded from the calculation of week-age-specific and standardized death rates.
3. Description of the week-specific mortality rates data file
Week-specific standardized death rates for Russia as a whole and its regions are contained in a single data file presented in .csv format. The format of data allows its uploading into any system for statistical analysis. Each record (row) in the data file contains data for one calendar year, one week, one territory, one sex. 
The decimal point is dot (.) 
The first element of the row is the territory code ("PopCode" column), the second element is the year ("Year" column), the third element ("Week" column) is the week of the year, the fourth element ("Sex" column) is sex (F – female, M – male, B – both sexes combined). This is followed by a column "CDR" with the value of the crude death rate and  "SDR" with the value of the standardized death rate.  If the indicator cannot be calculated for some combination of year, sex, and territory, then the corresponding meaningful data elements in the data file are replaced with ".".
DOI: 10.5281/zenodo.10280664
title: Russian Short-Term Mortality Fluctuations database

description: 1. Database contents
The Russian Short-Term Mortality Fluctuations database (RusSTMF) contains a series of standardized and crude death rates for men, women and both sexes for Russia as a whole and its regions for the period from 2000 to 2021.
All the output indicators presented in the database are calculated based on data of deaths registered by the Vital Registry Office. The weekly death counts are calculated based on depersonalized individual data provided by the Russian Federal State Statistics Service (Rosstat) at the request of the HSE. Time coverage: 03.01.2000 (Week 1) – 31.12.2021 (Week 1148)
2. A brief description of the input data on deaths
Date of death: date of occurrence
Unit of time: week
First and last days of the week: Monday – Sunday
First and last week of the year: The weeks are organized according to ISO 8601:2004 guidelines. Each week of the year, including the first and last, contains 7 days. In order to get 7-day weeks, the days of previous years are included in this first week (if January 1 fell on Tuesday, Wednesday or Thursday) or in the last calendar week (if December 31 fell on Thursday, Friday or Saturday).
Age groups: the entire population
Sex: men, women, both sexes (men and women combined)
Restrictions and data changes: data on deaths in the Pskov region were excluded for weeks 9-13 of 2012
Note: Deaths with an unknown date of occurrence (unknown year, month, or day) account for about 0.3% of all deaths and are excluded from the calculation of week-age-specific and standardized death rates.
3. Description of the week-specific mortality rates data file
Week-specific standardized death rates for Russia as a whole and its regions are contained in a single data file presented in .csv format. The format of data allows its uploading into any system for statistical analysis. Each record (row) in the data file contains data for one calendar year, one week, one territory, one sex. 
The decimal point is dot (.) 
The first element of the row is the territory code ("PopCode" column), the second element is the year ("Year" column), the third element ("Week" column) is the week of the year, the fourth element ("Sex" column) is sex (F – female, M – male, B – both sexes combined). This is followed by a column "CDR" with the value of the crude death rate and  "SDR" with the value of the standardized death rate.  If the indicator cannot be calculated for some combination of year, sex, and territory, then the corresponding meaningful data elements in the data file are replaced with ".".
DOI: 10.6084/m9.figshare.24762996
title: code/data for https://www.biorxiv.org/content/10.1101/811992v3

description: <b>Abstract of the study, from our pre-print:</b> Until now it has been difficult to examine the neural bases of foraging in naturalistic environments because previous approaches have relied on restrained animals performing trial-based foraging tasks. Here, we allowed unrestrained monkeys to freely interact with concurrent reward options while we wirelessly recorded population activity in the dorsolateral prefrontal cortex (dlPFC). The animals decided when and where to forage based on whether their reward prediction was fulfilled or violated. This prediction was not solely based on a history of reward delivery but also on the understanding that waiting longer improves the chance of reward. The decoded reward dynamics were continuously represented in a subspace of the high-dimensional population activity and predicted the animal’s subsequent choice better than the true experimental variables and as well as the raw neural activity. Our results indicate that monkeys’ foraging strategy is based on a cortical model of reward dynamics as animals freely explore their environment.